SI-BONE, Inc. (NASDAQ:SIBN) Receives $23.00 Consensus Price Target from Analysts

Shares of SI-BONE, Inc. (NASDAQ:SIBN) have been assigned an average rating of “Buy” from the six brokerages that are presently covering the company, MarketBeat reports. Six equities research analysts have rated the stock with a buy recommendation. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $23.00.

Several brokerages have recently commented on SIBN. Needham & Company LLC restated a “buy” rating and issued a $19.00 price objective on shares of SI-BONE in a research report on Wednesday, November 20th. Truist Financial raised their target price on shares of SI-BONE from $16.00 to $18.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Finally, Morgan Stanley decreased their price target on shares of SI-BONE from $21.00 to $19.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 6th.

SI-BONE Trading Up 0.7 %

SI-BONE stock opened at $12.65 on Friday. The company has a quick ratio of 7.22, a current ratio of 8.25 and a debt-to-equity ratio of 0.22. The company has a market cap of $530.54 million, a P/E ratio of -13.75 and a beta of 1.22. The business has a 50-day simple moving average of $13.67 and a two-hundred day simple moving average of $14.18. SI-BONE has a 52-week low of $11.70 and a 52-week high of $21.70.

Insiders Place Their Bets

In other SI-BONE news, CEO Laura Francis sold 10,048 shares of SI-BONE stock in a transaction on Monday, November 18th. The shares were sold at an average price of $12.58, for a total transaction of $126,403.84. Following the sale, the chief executive officer now owns 482,875 shares of the company’s stock, valued at $6,074,567.50. The trade was a 2.04 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Anthony J. Recupero sold 3,937 shares of the stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $12.60, for a total transaction of $49,606.20. Following the completion of the sale, the insider now owns 228,554 shares of the company’s stock, valued at approximately $2,879,780.40. The trade was a 1.69 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 23,093 shares of company stock valued at $299,558. 3.90% of the stock is owned by insiders.

Institutional Trading of SI-BONE

A number of hedge funds and other institutional investors have recently modified their holdings of SIBN. Rhumbline Advisers raised its stake in shares of SI-BONE by 1.5% in the 2nd quarter. Rhumbline Advisers now owns 59,419 shares of the company’s stock valued at $768,000 after acquiring an additional 852 shares during the period. Arizona State Retirement System grew its position in shares of SI-BONE by 9.0% during the second quarter. Arizona State Retirement System now owns 10,921 shares of the company’s stock worth $141,000 after buying an additional 903 shares in the last quarter. The Manufacturers Life Insurance Company increased its position in shares of SI-BONE by 7.5% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 15,880 shares of the company’s stock valued at $205,000 after purchasing an additional 1,105 shares during the last quarter. FMR LLC increased its holdings in shares of SI-BONE by 103.6% in the 3rd quarter. FMR LLC now owns 2,354 shares of the company’s stock valued at $33,000 after acquiring an additional 1,198 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD grew its position in shares of SI-BONE by 7.2% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 20,494 shares of the company’s stock valued at $336,000 after buying an additional 1,372 shares during the last quarter. 98.11% of the stock is owned by institutional investors and hedge funds.

About SI-BONE

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.